Literature DB >> 22128250

The polio-eradication programme and issues of the end game.

Philip D Minor1.   

Abstract

Poliovirus causes paralytic poliomyelitis, an ancient disease of humans that became a major public-health issue in the 20th century. The primary site of infection is the gut, where virus replication is entirely harmless; the two very effective vaccines developed in the 1950s (oral polio vaccine, or OPV, and inactivated polio vaccine, or IPV) induce humoral immunity, which prevents viraemic spread and disease. The success of vaccination in middle-income and developing countries encouraged the World Health Organization to commit itself to an eradication programme, which has made great advances. The features of the infection, including its largely silent nature and the ability of the live vaccine (OPV) to evolve and change in vaccine recipients and their contacts, make eradication particularly challenging. Understanding the pathogenesis and virology of the infection is of major significance as the programme reaches its conclusion.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22128250     DOI: 10.1099/vir.0.036988-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  20 in total

1.  A Temperature-Dependent Translation Defect Caused by Internal Ribosome Entry Site Mutation Attenuates Foot-and-Mouth Disease Virus: Implications for Rational Vaccine Design.

Authors:  Decheng Yang; Chao Sun; Rongyuan Gao; Haiwei Wang; Wenming Liu; Kewei Yu; Guohui Zhou; Bo Zhao; Li Yu
Journal:  J Virol       Date:  2020-07-30       Impact factor: 5.103

Review 2.  Clearing Vaccine-Derived Poliovirus Infection Following Hematopoietic Stem Cell Transplantation: a Case Report and Review of Literature.

Authors:  Mohammadreza Shaghaghi; Mona Irannejad; Hassan Abolhassani; Shohreh Shahmahmoodi; Amir Ali Hamidieh; Saeed Soleyman-Jahi; Reza Yazdani; Gholamreza Azizi; Asghar Aghamohammadi
Journal:  J Clin Immunol       Date:  2018-06-14       Impact factor: 8.317

3.  Robustness against serum neutralization of a poliovirus type 1 from a lethal epidemic of poliomyelitis in the Republic of Congo in 2010.

Authors:  Jan Felix Drexler; Gilda Grard; Alexander N Lukashev; Liubov I Kozlovskaya; Sindy Böttcher; Gökhan Uslu; Johan Reimerink; Anatoly P Gmyl; Raphaël Taty-Taty; Sonia Etenna Lekana-Douki; Dieudonné Nkoghe; Anna M Eis-Hübinger; Sabine Diedrich; Marion Koopmans; Eric M Leroy; Christian Drosten
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-18       Impact factor: 11.205

Review 4.  HPV vaccination in boys and men.

Authors:  Margaret Stanley
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 5.  The polio endgame.

Authors:  Philip Minor
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 6.  Poliomyelitis is a current challenge: long-term sequelae and circulating vaccine-derived poliovirus.

Authors:  Jorge Quarleri
Journal:  Geroscience       Date:  2022-10-19       Impact factor: 7.581

7.  Effect of formaldehyde inactivation on poliovirus.

Authors:  Thomas Wilton; Glynis Dunn; David Eastwood; Philip D Minor; Javier Martin
Journal:  J Virol       Date:  2014-08-06       Impact factor: 5.103

8.  Future vaccines for a globalized world.

Authors:  Lorne A Babiuk; Volker Gerdts
Journal:  Emerg Microbes Infect       Date:  2012-07       Impact factor: 7.163

9.  Seroepidemiology of human enterovirus71 and coxsackievirusA16 among children in Guangdong province, China.

Authors:  Wei Li; Lina Yi; Juan Su; Jing Lu; Hanri Zeng; Dawei Guan; Cong Ma; Wanly Zhang; Hong Xiao; Hui Li; Yonghui Zhang; Jinyan Lin; Changwen Ke
Journal:  BMC Infect Dis       Date:  2013-07-15       Impact factor: 3.090

Review 10.  Global mapping of infectious disease.

Authors:  Simon I Hay; Katherine E Battle; David M Pigott; David L Smith; Catherine L Moyes; Samir Bhatt; John S Brownstein; Nigel Collier; Monica F Myers; Dylan B George; Peter W Gething
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2013-02-04       Impact factor: 6.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.